Related Experiment Video
Updated: May 12, 2026
Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors
Published on: October 17, 2025
Identification of novel FLT3 kinase inhibitors
Daphnie Pauwels1, Hugo Klaassen, Idoya Lahortiga
1Center for the Biology of Disease, VIB, Leuven 3000, Belgium.
Abstract:
FLT3 and PDGFR tyrosine kinases are important targets for therapy of different types of leukemia. Several FLT3/PDGFR inhibitors are currently under clinical investigation for combination with standard therapy for treatment of acute myeloid leukemia (AML), however these agents only induce partial remission and development of resistance has been reported. In this work we describe the identification of potent and novel dual FLT3/PDGFR inhibitors that resulted from our efforts to screen a library of 25,607 small molecules against the FLT3 dependent cell line MOLM-13 and the PDGFR dependent cell line EOL-1. This effort led to the identification of five compounds that were confirmed to be active on additional FLT3 dependent cell lines (cellular EC50 values between 35 and 700 nM), while having no significant effect on 24 other tyrosine kinases.
Insights
Researchers identified novel dual FLT3/PDGFR inhibitors for leukemia treatment. These potent compounds show activity in cell lines, offering potential new therapeutic options beyond current treatments for acute myeloid leukemia (AML).
Area of Science:
- Oncology
- Pharmacology
- Biochemistry
Background:
- FMS-like tyrosine kinase 3 (FLT3) and Platelet-Derived Growth Factor Receptor (PDGFR) are key targets in leukemia therapy.
- Current FLT3/PDGFR inhibitors show limited efficacy and resistance issues in acute myeloid leukemia (AML) treatment.
Purpose of the Study:
- To identify novel, potent dual inhibitors targeting both FLT3 and PDGFR.
- To discover new therapeutic agents for leukemia with improved efficacy and reduced resistance.
Main Methods:
- Screening of a library of 25,607 small molecules.
- Utilized FLT3-dependent (MOLM-13) and PDGFR-dependent (EOL-1) cell lines for initial screening.
- Confirmed activity on additional FLT3-dependent cell lines and assessed selectivity against 24 other tyrosine kinases.
Main Results:
- Identified five potent dual FLT3/PDGFR inhibitors.
- Compounds demonstrated cellular EC50 values ranging from 35 to 700 nM against FLT3-dependent cell lines.
- The identified inhibitors showed no significant activity against 24 other tested tyrosine kinases, indicating selectivity.
Conclusions:
- The identified compounds represent novel and potent dual FLT3/PDGFR inhibitors.
- These novel inhibitors hold promise for developing new combination therapies for acute myeloid leukemia (AML).
- Further investigation is warranted to explore their therapeutic potential and overcome resistance mechanisms.